BridgeBio Pharma revenue and financials
$66.14Change from previous close: −1.65%Absolute change: −$1.11
In the fiscal year ended December 2025, BridgeBio Pharma reported revenue of $502.08M (+126.26% year over year). The net loss was $732.94M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +126.26%
- 2025 vs 2024
- Net margin
- -146.0%
- 2024: -244.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Total revenue | 502 | 222 | 9.3 | 77.6 | 69.7 | 8.2 | 40.6 |
| Cost of revenue | 21.0 | 3.9 | 2.4 | 3.4 | 3.1 | — | — |
| Gross profit | 481 | 218 | 6.9 | 74.2 | — | — | — |
| Selling, general and administrative | 531 | 289 | 151 | 143 | — | — | — |
| Research and development | 452 | 506 | 456 | 399 | 451 | 337 | 210 |
| Operating income | -523 | -593 | -607 | -512 | -577 | -474 | -266 |
| EBIT | -554 | -443 | -572 | -404 | — | — | — |
| EBITDA | -549 | -437 | -565 | -397 | — | — | — |
| Interest expense | 178 | 99.3 | 81.3 | 80.4 | 46.8 | 36.7 | 8.8 |
| Pre-tax income | -733 | -542 | -653 | -485 | — | — | — |
| Income tax | 0.4 | 1.2 | 0.0 | 0.0 | — | — | — |
| Net income | -733 | -543 | -653 | -485 | -586 | -505 | -289 |
| Net income to common shareholders | -725 | -536 | -643 | -481 | — | — | — |
| Basic EPS | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | — |
| Diluted EPS | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | — |
| Average shares (basic) | 192 | 186 | 163 | 147 | — | — | — |
| Average shares (diluted) | 192 | 186 | 163 | 147 | 144 | 118 | — |